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Abstract
Prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3) exerts chymotrypsin-like proteolytic activity. The main
biological function of PSA is the liquefaction of the clot formed after ejaculation by cleavage of semenogelins I and II in
seminal fluid. PSA also cleaves several other substrates, which may explain its putative functions in prostate cancer and its
antiangiogenic activity. We compared the proteolytic efficiency of PSA towards several protein and peptide substrates and
studied the effect of peptides stimulating the activity of PSA with these substrates. An endothelial cell tube formation
model was used to analyze the effect of PSA-degraded protein fragments on angiogenesis. We showed that PSA degrades
semenogelins I and II much more efficiently than other previously identified protein substrates, e.g., fibronectin, galectin-3
and IGFBP-3. We identified nidogen-1 as a new substrate for PSA. Peptides B2 and C4 that stimulate the activity of PSA
towards small peptide substrates also enhanced the proteolytic activity of PSA towards protein substrates. Nidogen-1,
galectin-3 or their fragments produced by PSA did not have any effect on endothelial cell tube formation. Although PSA
cleaves several other protein substrates, in addition to semenogelins, the physiological importance of this activity remains
speculative. The PSA levels in prostate are very high, but several other highly active proteases, such as hK2 and trypsin, are
also expressed in the prostate and may cleave protein substrates that are weakly cleaved by PSA.
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Introduction
Proteases have a significant influence on tumor growth, invasion
and formation of metastases [1]. Increased proteolytic activity in
the tumor microenvironment has been associated with cancer
progression, as degradation of extracellular matrix components is
needed for cancer cell migration and invasion [2]. Proteases may
also exert several other functions relevant in cancer, including
activation of protease activated receptors (PARs) and regulation of
the activity of other signaling molecules, such as kinases and
growth factors [3,4]. However, the role of proteases in cancer is
not straightforward, as individual proteases interact with each
other in complex proteolytic networks, and some proteases have
been found to have tumor-suppressive functions [1,2,5], thus,
besides facilitating cell invasion, matrix metalloproteinases may
also inhibit cancer cell growth, induce apoptosis and produce
antiangiogenic fragments from plasminogen and collagen type IV
[6,7].
The prostate produces several proteases, the expression of
which varies during prostate cancer development [8,9]. The most
abundant protease expressed in the prostate and secreted into the
seminal fluid is prostate-specific antigen (PSA or kallikrein-related
peptidase-3, KLK3), a well-known biomarker of prostate cancer
[10–12]. In spite of its clinical importance, the functional role of
PSA in prostate cancer is not well understood [9,13]. PSA is a
28 kDa serine protease with chymotrypsin-like enzymatic activity
[14,15]. The known physiological function of PSA is degradation
of the gel-forming proteins semenogelins I and II in semen after
ejaculation [16]. This leads to liquefaction of the seminal clot and
the release of motile sperm, thus enabling the spermatozoa to
travel through the female reproductive tract [17,18]. Also, several
other functions have been suggested for PSA, most of which
depend on its proteolytic activity [8,9]. These proposed functions
have mainly been studied using in vitro methods and it is not
known whether they are relevant for prostate cancer development
or normal physiology.
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Several studies have demonstrated that PSA exerts antiangio-
genic activity in vitro and in vivo [19–22]. By using an endothelial
cell tube formation model, we have shown that the enzymatic
activity of PSA is essential for this activity [23]. Previously, PSA
has been shown to cleave components of the extracellular matrix
(ECM), e.g., laminin and fibronectin, as well as unidentified
proteins in the basement membrane preparation Matrigel [24–
26]. Proteolytic products of some ECM proteins are known to
inhibit angiogenesis [27], but degradation of ECM is also crucial
for cancer cell invasion.
Previously, we have used phage display to identify peptides that
bind to PSA and stimulate its proteolytic activity towards a small
chromogenic substrate [28]. These peptides also enhance the
antiangiogenic activity of PSA in the tube formation model [29]
and have been suggested to be useful lead molecules for the
development of new prostate cancer treatments [30].
In this study we compared the proteolytic activity of PSA, with
and without the PSA-activity stimulating peptides, towards two
small peptide substrates and several putative protein substrates. By
studying protein fragments cleaved by PSA in Matrigel we showed
that nidogen-1 (also known as entactin), a linker protein in the
basement membrane [31], is a novel PSA substrate. As nidogen-1
and galectin-3 have been associated with angiogenesis, we studied
whether they or their proteolytic fragments would affect angio-
genesis in an endothelial cell tube formation model. Comparison
of the cleavage of different protein substrates by PSA showed that
semenogelins I and II were degraded much more efficiently than
other protein substrates. Thus the physiological relevance of the
proteolytic activity of PSA towards protein substrates other than
semenogelins remains unclear.
Materials and Methods
Proteins and peptides
The major form of active PSA (isoform PSA-B) was purified
from pooled human seminal fluid by immunoaffinity chromatog-
raphy [32] followed by anion exchange chromatography [33].
Semenogelins I and II were isolated from human seminal fluid as
previously described [34], but instead of alkylating the proteins,
the reducing agent 30 mM dithiothreitol (Sigma-Aldrich, St.
Louis, MO) was included in all buffers during purification.
Semenogelins were stored in the purification buffer containing
2 M urea and 5 mM EDTA at 270uC. Prior to cleavage by PSA,
the buffer was exchanged to 50 mM Tris, pH 7.7, containing
0.15 M NaCl (TBS), with Amicon Ultra centrifugal filter units
(MW cut-off 30 kDa) (Millipore, Cork, Ireland) at 4uC, and
protein concentration was determined by measuring absorbance at
280 nm.
Fibronectin from human plasma (BD Biosciences, Bedford,
MA), recombinant human insulin-like growth factor-binding
protein-3 (IGFBP-3) (PeproTech, London, UK), recombinant
human nidogen-1 and galectin-3 (R&D Systems, Minneapolis,
MN), recombinant human matrix metalloproteinase-3 (MMP-3)
catalytic domain (Calbiochem, Darmstadt, Germany), bovine a-
chymotrypsin (Millipore, Freehold, NJ), plasminogen (Calbiochem
and Hyphen BioMed, Neuville-sur-Oise, France) and lys-plasmin-
ogen from human plasma (American Diagnostica, Stamford, CT)
were commercially obtained. Protein LoBind tubes (Eppendorf
AG, Hamburg, Germany) were used in all protein degradation
experiments.
Peptides that bind to PSA and stimulate its activity have
previously been identified by phage display [28]. The 13-amino
acid double cyclic peptide C4 (CVAYCIEHHCWTC, with
disulfide bridges between cysteines 1–13 and 5–10), the 12- amino
acid cyclic peptide B2 (CVFAHNYDYLVC, with a disulfide
bridge between cysteines 1–12) with and without C-terminal
amidation (B2-NH2 and B2, respectively) and an inactive
derivative of peptide B2-NH2 (B2-NH2-control, CVFAHNA-
DALVC, with a disulfide bridge between cysteines 1–12) were
purchased from AnaSpec (San Jose, CA), NeoMPS (Strasbourg,
France), Biomatik (Cambridge, Ontario, Canada) or GenScript
(Piscataway, NJ) as custom peptides. The purity of the peptides as
determined by HPLC was over 95% in all batches. We have not
observed any significant variation in the capacity of the peptides to
stimulate the PSA activity between different peptide batches and
suppliers.
Enzyme kinetics of PSA
The proteolytic activity of PSA towards small peptide substrates
was compared with two different substrates [35]. Both assays were
performed in 96-well microplates (PerkinElmer, Turku, Finland)
with duplicates in two separate experiments (n = 2) in TBS buffer
containing 1 g/l bovine serum albumin (0.1% BSA-TBS). The
chromogenic chymotrypsin substrate S-2586 (MeO-Suc-Arg-Pro-
Tyr-pNA?HCl) (Chromogenix Instrumentation Laboratory, Mi-
lan, Italy) at 0.125–5 mM concentration or 0.125–2 mM fluoro-
genic PSA substrate 4-morpholinecarbonyl-HSSKLQ-AMC (7-
amido-4-methylcoumarin) (custom peptide from JPT Peptide
Technologies GmbH, Berlin, Germany) [36] were added to the
wells together with 175 nM (5 mg/ml) PSA. The absorbance was
measured at 405 nm immediately and at 5 min intervals for
30 min and fluorescence at 355/460 nm (excitation/emission)
after 10 min, 20 min, 40 min, 1 h, 2 h and 4 h incubation at
room temperature with a Victor 1420 Multilabel plate reader
(PerkinElmer). In the fluorogenic assays all wells contained 5%
dimethyl sulfoxide (DMSO).
The maximum velocity of the reaction (Vmax) and the Michaelis
constant (Km), i.e., substrate concentration at which the reaction
rate is half of the maximum, were evaluated for PSA with both
peptide substrates using Sigma Plot 11 with the Enzyme Kinetics
Module 1.3 (SYSTAT Software, Inc., San Jose, CA) and the
catalytic constant (kcat), i.e., the number of substrate molecules
converted to product per time unit, was calculated from the
equation kcat = Vmax/[PSA]. The absorbance was converted to
molar concentration with the Lambert-Beer equation (A = ecl),
using the molar absorptivity of pNA (epNA = 8800 M
21cm21).
Fluorescence (counts per second, cps) was transformed to molar
concentrations with SigmaPlot by means of a standard curve for 7-
amido-4-methylcoumarin (AMC, Sigma-Aldrich).
The effect of the PSA-stimulating peptides on the activity of
PSA was characterized with chromogenic and fluorogenic
substrates in two (n = 2) and three (n = 3) separate experiments,
respectively. PSA (350 nM) was first preincubated with peptides
(0.35–350 mM) for 30 min at room temperature. Then 0.2 mM
chromogenic or 0.3 mM fluorogenic substrate was added and
absorbance or fluorescence was measured as described above.
Fluorogenic assays with the peptides were performed in black 384-
well microplates (Corning Inc., Corning, NY) and all wells
contained 0.75% DMSO. The velocity of the reaction (V) was
calculated from the change of absorbance/min or fluorescence/
min at the linear phase of the reaction and converted to molar
concentration as described above. Vmax (peptide + PSA), i.e., the
maximal velocity of the reaction with increasing peptide concen-
trations and given PSA and substrate concentrations, was
determined using SigmaPlot, fitting the data to f = y0+a*(12
exp(2b*x)) using non-linear regression. The maximal stimulatory
capacity of the peptide, Vmax (peptide+PSA)/V(PSA), was calculated.
The peptide concentrations at which the stimulation of PSA was
Proteolytic Activity of PSA
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half of the maximum ([peptide]KVmax) and at which PSA activity
was increased two-fold when compared to PSA alone ([peptide]2V)
were also determined.
Surface plasmon resonance
The binding kinetics and affinity of the peptides stimulating the
activity of PSA were studied by surface plasmon resonance (SPR)
on a Biacore T100 instrument using Biacore T100 Control
Software 2.0.3 (both from GE Healthcare, Uppsala, Sweden). PSA
(20 mg/ml, 0.7 mM) and a-chymotrypsin (20 mg/ml, 0.8 mM) were
covalently immobilized on the Series S Sensor Chip CM5 (GE
Healthcare) by using amine coupling in 10 mM sodium acetate
buffer, pH 5.0. The immobilization levels varied in different
experiments between 2000–3900 resonance units (RU) for PSA
and 1400–2500 RU for chymotrypsin. Chymotrypsin was used as
a reference for PSA, i.e., the binding of peptides to the
chymotrypsin surface was subtracted as a non-specific interaction
from the binding of peptides to the PSA surface in all
measurements.
Binding to PSA was studied at various peptide concentrations
(1.2–600 mM) in phosphate buffered saline (PBS), pH 7.4 (Lonza,
Verviers, Belgium), containing 6.7 mM PO4 and 0.15 M NaCl,
with a flow rate of 40 ml/min at 25uC. Contact time of the
peptides with PSA was 60 s and dissociation time 180 s. In all
other steps except the peptide binding the running buffer was
supplemented with 0.005% surfactant P20 (GE Healthcare). The
chip was washed after each measurement cycle with the running
buffer, which removed all peptides. The binding data were
analyzed using Biacore T100 Evaluation software 2.0.3. (GE
Healthcare) with a Steady State Affinity model. The data from 3 to
4 independent experiments each with two replicates (n = 3 for B2
and n = 4 for B2-NH2 and C4) were analyzed by Mann-Whitney
U test and p-values,0.05 were considered significant.
Characterization of Matrigel degradation and mass
spectrometry
Matrigel basement membrane preparation (BD Biosciences)
with a protein concentration of 9.7 mg/ml was diluted 1:20 in
TBS. Matrigel proteins (250 mg/ml) were incubated with PSA
(200 mg/ml, 7.1 mM) in a 50 ml volume at 37uC for 48 h. A sample
containing 5 mg Matrigel proteins and 4 mg PSA was analyzed by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by
silver staining and Western blotting (see below).
For mass spectrometry, selected protein fragments were cut
from the silver-stained gel, reduced, alkylated with 55 mM
iodoacetamide and digested with modified trypsin (V511A,
Promega, Madison, WI) [37]. Peptide fragments were purified
using a ZipTip (ZipTipC18, Millipore, Billerica, MA), which was
wetted and equilibrated according to instructions. After sample
application, the tip was washed with 0.1% TFA and peptides
eluted with 3 ml of 40% ACN in 0.1% TFA and diluted with 21 ml
of 0.1% formic acid (FA). The extracted peptide sample (10 ml)
was separated on a RP-HPLC (CapLC, Waters, Manchester, UK)
with a C18 trap column (Atlantis dC18, NanoEase Trap Column,
5 mm, Waters) and a 0.0756150 mm C18 analytical column
(Atlantis dC18, 100 A˚, 3 mm, Waters) and eluted with a linear
gradient of ACN (from 5 to 50% in 30 min) in 0.1% FA at a flow
rate of 0.3 ml/min. MS analysis was performed online with a Q-
TOF Micro (Waters) with an ESI source. Fragmentation spectra of
the peptides were acquired by colliding doubly or triply charged
precursor ions with argon collision gas at accelerating voltages of
20–70 V. The MS was calibrated using 2 pmol/ml glufibrinogenic
peptide B fragments and the LC-MS repeatability was validated
using a commercial standard BSA-digest (Waters). For protein
identification the peaks were transformed to MGF files with
Progenesis LC-MS (version 2.4, Nonlinear Dynamics, Newcastle
on Tyne, UK) and searched using Mascot (version 2.2, in-house
server), Swissprot 2014_05 (545388 sequences, 193948795 resi-
dues) all taxonomy, and the following parameters: Enzyme:
Trypsin, Peptide Mass Tolerance: 0.2 Da, Fragment Mass
Tolerance: 0.5 Da, Max missed cleavages 1, fixed modification:
Carbamidomethyl (C), variable modification: oxidation (M). The
false discovery rate,5% was defined using the Decoy database
search in Mascot. The protein score was calculated based on ion
score cut-off 25 for individual peptides.
Proteolytic cleavage of PSA-substrates
PSA (0.2–1 mM) and 0.5–1 mM of each protein substrate were
incubated at 37uC for 22 h in TBS buffer. During the incubation,
samples of 15 ml were taken at different time points: 0 min,
10 min, 30 min, 2 h, 5 h and 22 h, and stored at 220uC before
further analysis. As a cleavage control, plasminogen was also
incubated with 1 mM MMP-3 at 37uC for 22 h in TBS.
To confirm that the substrates were cleaved by PSA and not by
possible contaminating proteases in the PSA preparation, we
inhibited the proteolytic activity of PSA by one-hour preincuba-
tion at room temperature with 0.4 mM (two-fold molar excess)
monoclonal antibody 5C7 that efficiently inhibits PSA, but not
hK2 (a structurally similar protease and a common contaminant in
PSA preparations) [38,39]. After this preincubation protein
substrates (1 mg for all, except for semenogelin I 0.6 mg) were
added for 20 h incubation at 37uC.
To study the effect of the PSA-binding peptides on the
proteolytic activity of PSA towards protein substrates, PSA
(0.1 mg, i.e., final concentration 0.2 mM) was first preincubated
for 30 min at room temperature with 1 or 5 mg of peptides B2 and
C4 (46 or 230 mM and 43 or 213 mM, respectively). Then 0.3–
2.5 mM protein substrates (i.e., 1 mg for all, except for semenogelin
I 0.6 mg) were added to the PSA-peptide mixture (final volume
15 ml) and incubated at 37uC for 10 min (semenogelin I), 40 min
(semenogelin II), 4 h (fibronectin and nidogen-1) or 20–22 h
(galectin-3 and IGFBP-3). Appropriate incubation time for each
substrate was chosen according to the degradation experiments
without peptides (above). Each peptide (5 mg) was also included as
a control without PSA.
Immediately after each incubation, reducing 46 SDS-loading
buffer (8% SDS), containing 1 M b-mercaptoethanol or 75 mM
dithiothreitol, was added to each sample and proteins were
denatured at 70uC for 10 min. The samples were immediately
analyzed by SDS-PAGE or frozen at 220uC. Frozen samples were
heated again at 70uC before loading on the gel. The cleavage of
protein substrates by PSA, i.e., the disappearance of the full-length
protein bands, was quantified from scanned images of silver
stained gels by the measurement of relative optical densities of the
protein bands using ImageJ [40].
For N-terminal sequencing, 1 mM (10 mg) nidogen-1 was first
incubated with 2 mM (5 mg) PSA for 22 h at 37uC. Then the
resulting protein fragments were separated by SDS-PAGE and
electroblotted onto polyvinylidene-difluoride (PVDF) membrane
[41]. After staining with Coomassie Brilliant Blue the protein
fragments were directly sequenced by Edman-degradation using
the Procise 494A Sequencer (Perkin Elmer Applied Biosystems,
Foster City, CA).
SDS-PAGE, silver staining and Western blotting
Proteins were separated using the XCell SureLock Mini Cell
system and pre-cast NuPAGE Novex 4–12% Bis-Tris Gels (both
from Invitrogen, Carlsbad, CA). MES running buffer, pH 7.3,
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containing 50 mM MES [2-(N-morpholino)ethanesulfonic acid]
(Sigma-Aldrich), 50 mM Tris base, 3.5 mM SDS and 1 mM
EDTA was used. Dithiothreitol (0.5 mM) (Sigma-Aldrich) was
added to the cathode buffer chamber.
Proteins were visualized either by silver staining or Western
blotting. For silver staining (modified from [42]), the gel was fixed
for one hour at room temperature in 30% ethanol, containing
0.5% acetic acid, and rinsed with 20% ethanol and water for
10 min each. Then the gel was sensitized with 0.02% sodium
thiosulfate for 1 min and rinsed twice with water. After 30 min
incubation in 0.2% AgNO3, the gel was rinsed briefly with water
and proteins were detected with development solution, containing
700 ml/l of 37% formaldehyde, 0.001% sodium thiosulfate and
3% anhydrous Na2CO3. The development reaction was finished
with stop solution containing 5% Tris and 2.5% acetic acid.
For Western blotting, proteins were transferred to an Im-
mobilon-P membrane (Millipore) by the Trans Blot semi-dry
transfer system (BioRad Laboratories, Hercules, CA). The
membrane was blocked over night at 4uC with 1% bovine serum
albumin (BSA) in TBS prior to incubation with 0.1 mg/ml goat
anti-nidogen-1 polyclonal antibody (AF2570, R&D Systems), and
detected with horseradish peroxidase-conjugated rabbit anti-goat
IgG (P0449, Dako, Glostrup, Denmark) using enhanced chemi-
luminescence (ECL) detection reagents (GE Healthcare, Buck-
inghamshire, UK).
Immunofluorometric assay for IGFBP-3
To study the degradation of IGFBP-3 by PSA, we used a
sandwich-type immunofluorometric assay (IFMA) that measures
only intact IGFBP-3, but not that cleaved by PSA [43,44]. PSA
(0.1 mg in 15 ml, i.e., 0.2 mM) and 1 mg (2.2 mM) IGFBP-3 were
incubated together at 37uC for 24 h in TBS buffer, with and
without 1 or 5 mg of peptides B2 and C4 (46 or 230 mM and 43 or
213 mM, respectively). After incubation, the samples were diluted
1:1000 in IFMA assay buffer and IGFBP-3 concentrations were
measured as previously described [43,44].
Cell culture and HUVEC tube formation assay
Human umbilical vein endothelial cells (HUVECs) were
isolated from umbilical cord veins and grown in Endothelial Cell
Growth Medium (Promocell, Heidelberg, Germany) with 2%
Ultroser G BioSepra serum substitute (PALL BioSepra, Cergy,
France) and growth factors EGF and bFGF. For tube formation,
HUVECs were grown on top of Matrigel (BD Biosciences) as
described previously [23,29].
To study the effect of PSA-cleaved protein fragments, 0.08 mM
nidogen-1 or 0.4 mM galectin-3 (10 mg/ml each) were first
incubated with 1 mM PSA for 24 h at 37uC in PBS (Lonza).
Then PSA activity was blocked by one-hour incubation at room
temperature with 2 mM monoclonal antibody 5C7 [38]. The
mixture containing nidogen-1 or galectin-3 fragments with PSA
blocked by antibody or the same amount of intact nidogen-1 or
galectin-3 were added together with the cells onto gelled Matrigel
and the cells were allowed to form tubular networks for 20 h.
Control wells contained either PBS or 1 mM PSA. After overnight
incubation, cell culture medium was collected from PBS and PSA
control wells for SDS-PAGE and Western blotting. Images of
tubular networks (1006magnification) were taken using an
Axiovert 200 inverted light microscope connected to an AxioCam
digital camera and visualized by AxioVision software (all from
Zeiss, Go¨ttingen, Germany).
Figure 1. Peptides stimulate PSA activity towards small
peptide substrates. Peptide C4 stimulated the activity of PSA (mean
6 SD) more efficiently than peptide B2-NH2 towards (A) a chromogenic
peptide substrate (n = 2) and (B) a fluorogenic peptide substrate (n = 3).
Dashed lines indicate the activity of PSA without peptide stimulation.
doi:10.1371/journal.pone.0107819.g001
Table 1. Enzyme kinetics of PSA with small peptide substrates.
Km kcat kcat/Km
(mM) (s21) (s21M21)
Chromogenic substratea 5.7261.53 0.7560.07 133.4624.6
Fluorogenic substrateb 1.5860.04 0.1960.09 122.0659.4
The values represent mean 6 SD of two experiments.
aS-2586, MeO-Suc-Arg-Pro-Tyr-pNA?HCl
b4-morpholinecarbonyl-HSSKLQ-AMC
doi:10.1371/journal.pone.0107819.t001
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Ethic statement
The isolation of HUVECs and the use of human seminal fluid
for PSA purification were approved by the Institutional Review
Board of Helsinki University Central Hospital. All participants
gave a written informed consent for the use of the cells or seminal
plasma for research.
Results
Characterization of PSA kinetics and effect of peptides on
the enzymatic activity
The enzyme kinetics of PSA were determined with two different
small peptide substrates (Table 1). These substrates were used to
characterize the kinetic parameters also with peptides that
stimulate the activity of PSA. Peptide C4 stimulated the activity
of PSA towards chromogenic and fluorogenic peptide substrates
six- to eight-fold, being more efficient than peptide B2-NH2, which
stimulated PSA activity four-fold (Figure 1, Table 2). The effect of
peptide B2 was similar to that of B2-NH2, while the inactive
control peptide, B2-NH2-control, did not stimulate PSA activity at
all (Figure 1A).
Binding affinity of the peptides to PSA
The binding kinetics and the affinity of the peptides (B2, B2-
NH2, B2-NH2-control and C4) to PSA were studied by surface
plasmon resonance. All peptides, except the inactive B2-NH2-
control peptide, bound to PSA. However, the association or
dissociation rate constants (ka and kd), could not be estimated
because the association of the peptides to and dissociation from
PSA were too fast for reliable measurement.
The equilibrium dissociation constant (KD), i.e., the binding
affinity, was calculated for each peptide from the equilibrium plot
showing the binding (RU) as a function of peptide concentration
(Figure S1). This showed that B2 (KD = 73.6620.3 mM, mean 6
SD) and B2-NH2 (KD = 56.565.3 mM) bound more strongly to
PSA than peptide C4 (KD = 197.8630.5) (p = 0.034 and p = 0.021,
respectively). There was no statistically significant difference in
binding affinity between B2 and B2-NH2 (p = 0.29).
Identification of nidogen-1 as a substrate for PSA
Matrigel, a basement membrane preparation of mouse origin,
was incubated with PSA and the degradation products were
analyzed by SDS-PAGE followed by silver staining. After
incubation, 110 and 140 kDa bands disappeared, while new
smaller bands of 55 and 90 kDa in size were observed (Figure 2).
Mass spectrometric analysis of these bands identified nidogen-1 as
a first hit with Mascot scores of 1057 (17 peptides from nidogen-1
identified), 1153 (18 peptides), 439 (9 peptides) and 1156 (17
peptides), respectively (Table S1). Furthermore, these bands
reacted with nidogen-1 antibody in Western blotting (Figure 2).
The cleavage of nidogen-1 by PSA was confirmed using
recombinant nidogen-1 (Figure 2). Weak staining of full-length
nidogen-1 was also observed by Western blotting in cell culture
medium samples, collected after HUVEC tube formation assay
performed on Matrigel, and nidogen-1 cleavage products were
observed when PSA was present in the assay (data not shown).
The cleavage site(s) of PSA in nidogen-1 were determined by N-
terminal sequencing of two fragments of recombinant nidogen-1
(55 and 85 kDa) resulting from incubation with PSA (Figure 2).
The N-terminal amino acids were G/(S), Y, N, T, D for the
55 kDa fragment and G/(S), (Y), (N), (T), (D) for the 85 kDa
fragment (amino acids in parenthesis were not identified with high
reliability). Based on this, the cleavage site for PSA in nidogen-1
was determined to be GVVF380Q SYNTD (numbering according
to the UniProt sequence P14543).
Table 2. Stimulation of PSA activity towards small peptide substrates with peptides B2-NH2 and C4.
Stimulation [peptide]KVmax [peptide]2V
(%) (mM) (mM)
Chromogenic substratea
B2-NH2 400614 5.1361.43 3.3360.83
C4 78567 5.6262.17 1.5560.54
Fluorogenic substrateb
B2-NH2 391611 4.7861.55 2.9461.07
C4 61068 3.7260.50 1.3660.25
Maximal stimulation capacity of the peptide as compared to PSA alone and peptide concentrations with half-maximal stimulation ([peptide]KVmax) and two-fold
stimulation of PSA activity ([peptide]2V) are shown. The values represent mean 6 SD (n = 2 for chromogenic and n= 3 for fluorogenic substrate).
a,bAs in Table 1.
doi:10.1371/journal.pone.0107819.t002
Figure 2. Degradation of nidogen-1 by PSA. PSA cleaved both
mouse nidogen-1 in Matrigel and human recombinant nidogen-1. Mass
spectrometry analysis identified nidogen-1 in the silver stained gel
bands (arrows, left panel). Nidogen-1 bands of 140 kDa (A) and 110 kDa
(B) disappeared and fragments of 90 kDa (C) and 55 kDa (D) appeared
after 48 h incubation of diluted Matrigel with PSA at 37uC. Nidogen-1
cleavage by PSA in Matrigel was visualized by Western blotting with
anti-nidogen-1 polyclonal antibody (middle panel). PSA (1 mM) cleaved
recombinant human nidogen-1 (0.5 mM) into two fragments 85 kDa
(arrow with *) and 55 kDa (arrow with **) during 20 h incubation at
37uC (right panel).
doi:10.1371/journal.pone.0107819.g002
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Cleavage of protein substrates and effect of stimulating
peptides
Several protein substrates were incubated together with PSA
and samples were drawn at different time points during incubation
for up to 22 h. PSA cleaved its physiological substrates
semenogelins very efficiently (Figure 3A). As determined by the
disappearance of the full-length protein bands, half of the intact
semenogelins I and II were degraded by PSA after 11 min and
80 min incubation, respectively. Fragments of fibronectin, galec-
tin-3, IGFBP-3 and nidogen-1 could be detected after 2–5 h
incubation with PSA, but extensive cleavage was readily seen only
after overnight incubation. Thus, 50% of fibronectin was degraded
in 17 h and of IGFBP-3 and nidogen-1 after 22 h.
Monoclonal antibody 5C7 inhibited the cleavage of all protein
substrates (Figure S2 and data not shown). In contrast to MMP-3,
PSA did not cleave plasminogen after 22 h incubation, even if
different plasminogen preparations and PSA batches were used
(Figure 3B).
Peptides B2 and C4 stimulated the activity of PSA towards
semenogelin I (10 min incubation with PSA), semenogelin II
(40 min incubation), fibronectin and nidogen-1 (4 h incubation),
and galectin-3 and IGFBP-3 (20–22 h incubation) (Figure 4A).
The extent and the relative efficiency of the stimulation of PSA
activity by the peptides were different from those observed with
small peptide substrates, peptide B2 being more effective than C4
with protein substrates (except with fibronectin the cleavage was
stimulated to a similar extent with B2 and C4). PSA decreased the
content of intact IGFBP-3 by 50% in 22 h as measured by the
immunofluorometric assay, which recognizes only full-length non-
proteolyzed IGFBP-3, and both peptides stimulated the proteolytic
activity of PSA towards IGFBP-3 further, peptide B2 being much
more efficient than C4 (Figure 4B).
Effect of nidogen-1 and galectin-3 on HUVEC tube
formation
The effect of nidogen-1 and galectin-3 and their fragments
generated by PSA was studied in the HUVEC tube formation
assay, in which PSA reduced tube formation indicating decreased
angiogenic potential of the cells (Figure 5). Neither PSA-produced
fragments of nidogen-1 or galectin-3, nor their full-length forms,
did have any effect on angiogenesis in this model.
Discussion
The kallikrein-related peptidase (KLK) family comprises 15
members, most of which exert trypsin-like enzymatic activity
[9,14]. PSA has chymotrypsin-like activity, although its specificity
is more restricted than that of chymotrypsin [45]. Furthermore,
the proteolytic activity of PSA is much weaker than that of
chymotrypsin or trypsin [14,36]. KLK7 also exerts chymotrypsin-
like activity, while KLK1, 10 and 11 have been reported to have
both tryptic and chymotryptic activities [46].
Previously, several selective and efficient substrates for PSA
have been described. We used a fluorogenic peptide substrate
identified by Denmeade and coworkers (1997) [36]. The specificity
constant kcat/Km, which is generally considered a measure of the
efficiency of an enzyme, was about five-fold higher in our study
compared to that reported by Denmeade et al. [36]. In previous
studies, the kcat/Km for PSA with the chromogenic substrate S-
2586 has also varied, being somewhat lower than that we observed
[15,47]. These differences may be explained by higher activity of
the highly pure active isoform of PSA used in this study [32,33],
differences in substrate preparations and/or minor differences in
assay conditions.
The concentration of PSA in seminal fluid varies between ,0.3
and 3 mg/ml (10–100 mM) and normally only trace amounts
reach circulation [12]. Active PSA forms complexes with protease
inhibitors and occurs in circulation mostly in an inactive form
[10,48]. In prostate cancer, the tissue architecture and the
secretory pathway to the prostatic ducts are disrupted leading to
increased leakage of PSA into extracellular fluid and circulation
[10,12,49], but the expression of PSA is actually lower in cancer
than in the normal prostate [50,51]. In the extracellular fluid of
prostate cancer tissue high PSA concentrations, around 2 mM,
have been measured with about 90% of the PSA being
enzymatically active [52]. The high concentrations of active PSA
in prostatic tissue may have implications in cancer development
and thus PSA could both enhance and inhibit the growth of
prostate cancer at different stages of cancer development [13,30].
While semenogelins I and II are considered to be the
physiological substrates of PSA [16,53], several other protein
substrates have previously been reported to be degraded by PSA
[9]. These proteins or their proteolytic fragments may either
promote or inhibit cancer progression, e.g., the cleavage of
fibronectin and laminin may be involved in cell invasion [25,26],
IGFBP-3 is associated with cell proliferation [44,54], galectin-3 is
involved in several processes including cell adhesion, proliferation,
apoptosis and angiogenesis [55,56] and plasminogen-derived
angiostatin-like fragments inhibit angiogenesis [20]. In addition
to these, PSA has been reported to cleave some unidentified
protein components of the Matrigel basement membrane prepa-
ration [26], in which we now identified nidogen-1 as a new
substrate for PSA. Nidogen-1 has a major structural role as a link
between laminin and collagen type IV in the basement membrane
[31,57]. Several proteases including leukocyte elastase, mast cell
chymase, plasma kallikrein, MMP-7, MMP-19 and cathepsin S
have been reported to cleave mouse nidogen-1, while cathepsin S
also cleaved recombinant human nidogen-1 [58–61]. As nidogen-
1 is an essential linker molecule in basement membranes, its
proteolytic cleavage may disrupt the basement membrane
structure [58,62].
In the present study, we compared the proteolytic activity of
PSA towards several protein substrates. As shown previously,
semenogelins are cleaved very effectively by PSA. Malm and
coworkers (2000) reported that more than half of semenogelin I is
degraded after 15 min incubation with PSA [16,63] and we
observed this after 11 min incubation. Proteolysis of the other
protein substrates, i.e., fibronectin, IGFBP-3, galectin-3 and
nidogen-1, took much longer, reflecting the high substrate
specificity of PSA for semenogelins. Although degradation of
proteins other than semenogelins is relatively slow, the concen-
tration of PSA in the prostate is very high and, thus, the
physiological relevance of the cleavage of other substrates by PSA
cannot be ruled out. In this respect it is noteworthy, that the
Figure 3. Cleavage of protein substrates by PSA. (A) Characterization of the proteolytic activity of PSA (0.2 mM) during 22 h incubation towards
different protein substrates (1 mM each, except 0.5 mM semenogelin I) by SDS-PAGE and silver staining. Approximate molecular weights of the
proteins are: PSA (28 kDa), semenogelin I (50 kDa), semenogelin II (63 kDa), fibronectin (220 kDa), galectin-3 (26 kDa), IGFBP-3 (30 kDa) and nidogen-
1 (130 kDa). The lanes in which ,50% of the proteins were cleaved are bordered. (B) 1 mM MMP-3 (22 kDa), but not PSA, cleaved 1 mM plasminogen
(88 kDa). Also 0.5 M fibronectin was incubated with 1 mM PSA as a control (SDS-PAGE with silver staining).
doi:10.1371/journal.pone.0107819.g003
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prostate also produces several other proteases, including trypsin
and other KLKs, that are highly active [44,64,65]. Protease
contamination in the PSA preparation used in this study was ruled
out by using a monoclonal antibody that specifically inhibited the
activity of PSA and prevented the proteolytic cleavage of all
protein substrates studied.
PSA has been shown to cleave its substrates preferentially after
amino acid residues tyrosine and glutamine and less commonly
after leucine and other residues [45,63,66,67]. Using N-terminal
sequencing we identified one cleavage site of PSA in recombinant
human nidogen-1, but most probably there are still one or more
cleavage sites, as the same N-terminus was found in two fragments
of different size. As other cleavages may take place, the resulting
smaller fragments could be further degraded becoming undetect-
able with SDS-PAGE and silver staining. The identified cleavage
site GVVF380 Q SYNTD is fairly typical for PSA, as there is
phenylalanine (F) at the P1 position and serine (S) at the P19
position [67,68]. Interestingly, another protease with chymotryp-
sin-like specificity, mast-cell chymase, has been reported to cleave
mouse nidogen-1 at the same site [58]. The cleavage site between
phenylalanine and serine (amino acids 380 and 381 in the UniProt
sequence P14543) is located between globular domains G1 and G2
in the link region of nidogen-1, which is highly sensitive to
proteolysis [31,58,62]. The cleavage occurs just before domain G2
and thus PSA releases domain G1 and most of the link region from
nidogen-1. Unlike domains G2 and G3, domain G1 is not
involved in the interaction with laminin or collagen type IV, but it
binds to fibulin-2, another crosslinking protein in the basement
membrane [69]. However, fibulin-2 binds also to the G2 and G3
domains. Thus, the biological significance of the cleavage of
nidogen-1 by PSA is unclear. On the contrary, the cleavage of
nidogen-1 by cathepsin S occurred at three sites within the G2 and
G3 domains. This was shown to abolish its binding to laminin and
collagen type IV, and thus inhibited the linker function of nidogen-
1 [61].
PSA has been shown to exert antiangiogenic activity both in
vitro and in vivo [19,21] and we have shown that enzymatic
activity is needed for this function [23,29]. However, the detailed
mechanism of the antiangiogenic activity of PSA remains unclear.
Some of the proteolytically produced fragments of extracellular
matrix (ECM) proteins act as endogenous angiogenesis inhibitors
[27] and may mediate the antiangiogenic effect of PSA.
Previously, PSA has been reported to cleave plasminogen to
angiostatin-like fragments that inhibit angiogenesis in vitro [20].
Although plasminogen was readily cleaved by MMP-3, different
batches of active PSA purified in our laboratory were not found to
generate any fragments using different plasminogen preparations.
Moreover, when we treated HUVECs with PSA, the antiangio-
genic effect was not associated with measurable levels of
angiostatin in cell culture samples as measured by an ELISA
immunoassay, which detects 100-fold lower levels of angiostatin
than those reported to reduce tube formation and 10-fold lower
levels needed for inhibition of migration [70,71] (Mattsson et al.
unpublished data). It is also noticeable that the reported PSA
cleavage sites in plasminogen [20], i.e., after lysine (K) and
glutamic acid (E), do not fit well with the known major cleavage
sites of PSA according to the peptidase database MEROPS [67].
Thus it is possible that the PSA used in the original study was
contaminated by other proteases that are able to cleave
plasminogen. Indeed, several PSA preparations have been found
to contain trypsin-like proteases [39].
Interestingly, galectin-3 has been reported to promote angio-
genesis and its 21 kDa fragment was shown to inhibit angiogenesis
induced by the full-length protein [55,72]. Nidogen-1 may also
play a role in angiogenesis as it is up-regulated in endothelial tip
cells during blood vessel formation [73]. However, our results
show that although PSA cleaves nidogen-1, overnight pre-
incubation of gelled Matrigel with PSA, followed by inhibition
of PSA with an antibody, did not inhibit endothelial cell tube
formation (Mattsson et al. unpublished data). This shows that the
Figure 4. The effect of peptides on the proteolytic cleavage of different protein substrates by PSA. (A) Peptide B2 enhanced the activity
of PSA towards all protein substrates more strongly than C4, except for fibronectin this could not be detected. The peptides were preincubated with
0.2 mM PSA for 30 min prior to addition of 0.3–2.5 mM protein substrates and the cleavage of the proteins was detected after 10 min (semenogelin I),
40 min (semenogelin II), 4 h (fibronectin and nidogen-1) and 20–22 h (galectin-3 and IGFBP-3) incubation at 37uC. The notation 5* indicates that 5 mg
of either peptide (with semenogelins I and II peptide C4, and with the other proteins B2) was added to the control sample. (B) Concentration of intact
IGFBP-3 after incubation with PSA and peptides shown in relation to IGFBP-3 control without added PSA as measured by immunofluorometric assay
that recognizes only intact, not cleaved IGFBP-3 (n = 2, mean 6 SD).
Figure 5. HUVEC tube formation assay with nidogen-1 and galectin-3. Nidogen-1 and galectin-3 or their PSA-generated fragments did not
have any effect on tube formation. Control wells are with PBS and PSA. Images are representative examples from two separate experiments.
doi:10.1371/journal.pone.0107819.g005
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antiangiogenic effect of PSA is most probably not due to a
proteolytic cleavage of nidogen-1 in Matrigel. Moreover, nidogen-
1 or galectin-3 or their fragments generated by PSA did not have
any effect on angiogenesis in the tube formation assay. It is
noteworthy, that this assay was optimized for angiogenesis
inhibition and therefore we did not detect any potential
stimulation of angiogenesis by full-length galectin-3.
The synthetic peptides that we originally identified by phage
display, stimulate the proteolytic activity of PSA most likely by
binding near its active site [28,74]. It has been predicted that
binding of the peptides stabilizes the kallikrein loop of PSA in an
open conformation and this would increase the proteolytic activity
[75]. When measured with chromogenic and fluorometric assay,
peptides B2, B2-NH2 and C4 greatly enhanced PSA activity
towards two different peptide substrates. Peptides B2 and B2-NH2
were equipotent, while peptide C4 was more active in this respect,
which is in keeping with earlier observations with the chromogenic
substrate [28,32]. These peptides have also been found to enhance
the antiangiogenic activity of PSA in the endothelial cell tube
formation assay, when added together with PSA in the cell culture
medium [29].
We found that the PSA-stimulating peptides B2 and C4
enhanced the activity of PSA towards all protein substrates
studied, but their relative efficiency was different from that found
with small peptide substrates. With all studied protein substrates,
except for fibronectin, peptide B2 was more efficient in stimulating
PSA activity, while C4 was more efficient with peptide substrates.
This may be explained by differences in the size and structure of
the PSA substrates. Although with some of the protein substrates
the peptides stimulated the activity of PSA dose-dependently, we
could not observe such dose-dependent stimulation when nidogen-
1 or fibronectin were used as substrates. The reason for this is
unclear, but may be due to high peptide concentrations used.
The interaction of the peptides with PSA was found to be very
fast as studied by surface plasmon resonance. Previously, when
these peptides were produced as fusion proteins with glutathione-
S-transferase (GST), their equilibrium dissociation constants (KD)
with PSA were about 20- to 60-fold lower than in our study, i.e.,
GST-peptides bound more strongly to PSA [28]. This is explained
by multivalent binding, as part of the GST-peptides existed as
multimers. In the present study, peptides B2 and B2-NH2 bound
more strongly to PSA than C4, but with GST-peptides the
opposite was observed [28].
Conclusions
In addition to efficient proteolysis of semenogelins, PSA exerted
weak proteolytic activity towards the other protein substrates
studied. A basement membrane protein, nidogen-1, was identified
as a new substrate for PSA. The cleavage of nidogen-1 by PSA
may lead to disruption of basement membrane structure and may
facilitate cancer cell invasion, but our results suggest that PSA-
generated nidogen-1 or galectin-3 fragments do not mediate the
antiangiogenic function of PSA. Thus, the mechanism of the
antiangiogenic properties of PSA remains to be clarified. Peptides
that stimulate the activity of PSA towards small peptide substrates
also enhanced the cleavage of protein substrates by PSA.
Interestingly, the PSA-activity stimulating peptide that showed
less efficient stimulation with peptide substrates was more efficient
with protein substrates.
Supporting Information
Figure S1 Interaction of the peptides with PSA as studied by
surface plasmon resonance. The representative examples of
sensorgrams and the corresponding equilibrium plots showing
the peptide binding (resonance unit, RU) as a function of the
concentration of (A) B2-NH2, (B) B2, (C) C4, and (D) B2-NH2-
control. The dissociation constants (KD) were derived from the
equilibrium plots from three to four separate experiments each
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Figure S2 The cleavage of protein substrates is inhibited by a
monoclonal antibody specific for PSA. PSA (0.2 mM) was
preincubated for one hour with mAb 5C7 (0.4 mM) prior to
incubation for 20 h with protein substrates (A) semenogelins I and
II, or (B) fibronectin and nidogen-1.
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Table S1 The nidogen-1 peptide sequences identified by Mascot
search in different gel bands (shown in Figure 2). All peptides with
ions score 25 are shown.
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